Investigational drug · Phase 2
SYHX2011
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 9, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "SYHX2011"
First trial start
2024
Apr 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYHX2011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYHX2011" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)Pivotal-lookingStatus unknown
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT05753865 · 454 participants (planned) · Start May 1, 2023 · Primary completion Sep 1, 2024
Drug: SYHX2011; Paclitaxel for injection (albumin-bound) · For: Advanced Breast Cancer
Sites: Shijiazhuang, China
- SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Chest HospitalAcademic, hospital or other
NCT07662811 · 396 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 31, 2027
Drug: SYHX2011; Carboplatin and 4 more · For: Non-Small Cell Lung Cancer
- A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011Not yet recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06354114 · 80 participants (planned) · Start Apr 2024 · Primary completion Oct 31, 2024
Drug: SYHX2011 · For: Advanced Breast Cancer
Sites: Harbin, China
- A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast CancerStatus unknown
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT05274893 · 28 participants (planned) · Start Mar 31, 2022 · Primary completion Sep 30, 2022
Drug: SYHX2011 and Abraxane® · For: Advanced Breast Cancer
Newest research
PubMed records naming it or its code names, newest first.
- Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.
Tang T, Wang J, Sun T, et al. · Biomol Biomed 2026
- Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.
Zhang L, Wang J, Sun T, et al. · Cancer Commun (Lond) 2026
Also in development for Advanced Breast Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- PalazestrantOP-1250Phase 32 trials
Olema Oncology, Inc. · Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- RYZ101Phase 32 trials
RayzeBio, Inc. · Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer
- XZP-3287Phase 32 trials
Xuanzhu Biopharmaceutical Co., Ltd. · Advanced Breast Cancer
- ZovegalisibPhase 31 trial
Relay Therapeutics, Inc. · PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.